Immunoregulation and Antidepressant Effect of Ketamine

Overview

Journal Transl Neurosci

Specialty Neurology

Date 2021 Jun 3

PMID 34079622

Citations 9

Authors

Nan Zhang

Lihua Yao

Peilin Wang

Zhongchun Liu

Affiliations

Soon will be listed here.

Abstract

Major depressive disorder (MDD) is a common mental health disorder that brings severe disease burden worldwide. Traditional antidepressants are mainly targeted at monoamine neurotransmitters, with low remission rates and high recurrence rates. Ketamine is a noncompetitive glutamate -methyl-d-aspartate receptor (NMDAR) antagonist, and its rapid and powerful antidepressant effects have come to light. Its antidepressant mechanism is still unclarified. Research found that ketamine had not only antagonistic effect on NMDAR but also strong immunomodulatory effect, both of which were closely related to the pathophysiology of MDD. Although there are many related studies, they are relatively heterogeneous. Therefore, this review mainly describes the immune mechanisms involved in MDD and how ketamine plays an antidepressant role by regulating peripheral and central immune system, including peripheral inflammatory cytokines, central microglia, and astrocytes. This review summarizes the related research, finds out the deficiencies of current research, and provides ideas for future research and the development of novel antidepressants.

Citing Articles

Epigenetic mechanisms of rapid-acting antidepressants.

Inserra A, Campanale A, Rezai T, Romualdi P, Rubino T Transl Psychiatry. 2024; 14(1):359.

PMID: 39231927 PMC: 11375021. DOI: 10.1038/s41398-024-03055-y.

Effects of Mild Closed-Head Injury and Subanesthetic Ketamine Infusion on Microglia, Axonal Injury, and Synaptic Density in Sprague-Dawley Rats.

Boese M, Berman R, Qiu J, Spencer H, Radford K, Choi K Int J Mol Sci. 2024; 25(8).

PMID: 38673871 PMC: 11050690. DOI: 10.3390/ijms25084287.

Intermittent versus continuous esketamine infusions for long-term pain modulation in complex regional pain syndrome: protocol of a randomized controlled non-inferiority study (KetCRPS-2).

Mangnus T, Dirckx M, Bharwani K, Baart S, Siepman T, Redekop K BMC Musculoskelet Disord. 2023; 24(1):239.

PMID: 36991381 PMC: 10050795. DOI: 10.1186/s12891-023-06258-4.

The Downstaging Concept in Treatment-Resistant Depression: Spotlight on Ketamine.

Wilkowska A, Cubala W Int J Mol Sci. 2022; 23(23).

PMID: 36498934 PMC: 9738502. DOI: 10.3390/ijms232314605.

The Missing Piece? A Case for Microglia's Prominent Role in the Therapeutic Action of Anesthetics, Ketamine, and Psychedelics.

VanderZwaag J, Halvorson T, Dolhan K, Simoncicova E, Ben-Azu B, Tremblay M Neurochem Res. 2022; 48(4):1129-1166.

PMID: 36327017 DOI: 10.1007/s11064-022-03772-0.

References

Dello Russo C, Lisi L, Feinstein D, Navarra P . mTOR kinase, a key player in the regulation of glial functions: relevance for the therapy of multiple sclerosis. Glia. 2012; 61(3):301-11. DOI: 10.1002/glia.22433. View

Schoenfeld T, McCausland H, Morris H, Padmanaban V, Cameron H . Stress and Loss of Adult Neurogenesis Differentially Reduce Hippocampal Volume. Biol Psychiatry. 2017; 82(12):914-923. PMC: 5683934. DOI: 10.1016/j.biopsych.2017.05.013. View

Musselman D, Lawson D, Gumnick J, Manatunga A, Penna S, Goodkin R . Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med. 2001; 344(13):961-6. DOI: 10.1056/NEJM200103293441303. View

Syed S, Beurel E, Loewenstein D, Lowell J, Craighead W, Dunlop B . Defective Inflammatory Pathways in Never-Treated Depressed Patients Are Associated with Poor Treatment Response. Neuron. 2018; 99(5):914-924.e3. PMC: 6151182. DOI: 10.1016/j.neuron.2018.08.001. View

Chen T, Chang C, Lin Y, Ueng Y, Chen R . Signal-transducing mechanisms of ketamine-caused inhibition of interleukin-1 beta gene expression in lipopolysaccharide-stimulated murine macrophage-like Raw 264.7 cells. Toxicol Appl Pharmacol. 2009; 240(1):15-25. DOI: 10.1016/j.taap.2009.06.013. View

Boyko A . Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence. Expert Opin Biol Ther. 2010; 10(4):653-66. DOI: 10.1517/14712591003702361. View

Felger J, Li L, Marvar P, Woolwine B, Harrison D, Raison C . Tyrosine metabolism during interferon-alpha administration: association with fatigue and CSF dopamine concentrations. Brain Behav Immun. 2012; 31:153-60. PMC: 3578984. DOI: 10.1016/j.bbi.2012.10.010. View

Neurauter G, Schrocksnadel K, Scholl-Burgi S, Sperner-Unterweger B, Schubert C, Ledochowski M . Chronic immune stimulation correlates with reduced phenylalanine turnover. Curr Drug Metab. 2008; 9(7):622-7. DOI: 10.2174/138920008785821738. View

Bech P, Tanghoj P, Cialdella P, Andersen H, Pedersen A . Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression. Int J Neuropsychopharmacol. 2004; 7(3):283-90. DOI: 10.1017/S1461145704004365. View

10.

Lucassen P, Muller M, Holsboer F, Bauer J, Holtrop A, Wouda J . Hippocampal apoptosis in major depression is a minor event and absent from subareas at risk for glucocorticoid overexposure. Am J Pathol. 2001; 158(2):453-68. PMC: 1850286. DOI: 10.1016/S0002-9440(10)63988-0. View

11.

Fernandes A, Li Y . Focused microwave irradiation-assisted immunohistochemistry to study effects of ketamine on phospho-ERK expression in the mouse brain. Brain Res. 2017; 1670:86-95. DOI: 10.1016/j.brainres.2017.05.008. View

12.

Lamers F, Milaneschi Y, Smit J, Schoevers R, Wittenberg G, Penninx B . Longitudinal Association Between Depression and Inflammatory Markers: Results From the Netherlands Study of Depression and Anxiety. Biol Psychiatry. 2019; 85(10):829-837. DOI: 10.1016/j.biopsych.2018.12.020. View

13.

Leighton S, Nerurkar L, Krishnadas R, Johnman C, Graham G, Cavanagh J . Chemokines in depression in health and in inflammatory illness: a systematic review and meta-analysis. Mol Psychiatry. 2017; 23(1):48-58. PMC: 5754468. DOI: 10.1038/mp.2017.205. View

14.

Verdonk F, Petit A, Abdel-Ahad P, Vinckier F, Jouvion G, De Maricourt P . Microglial production of quinolinic acid as a target and a biomarker of the antidepressant effect of ketamine. Brain Behav Immun. 2019; 81:361-373. DOI: 10.1016/j.bbi.2019.06.033. View

15.

OBrien S, Scully P, Fitzgerald P, Scott L, Dinan T . Plasma cytokine profiles in depressed patients who fail to respond to selective serotonin reuptake inhibitor therapy. J Psychiatr Res. 2006; 41(3-4):326-31. DOI: 10.1016/j.jpsychires.2006.05.013. View

16.

Zhang K, Sakamoto A, Chang L, Qu Y, Wang S, Pu Y . Splenic NKG2D confers resilience versus susceptibility in mice after chronic social defeat stress: beneficial effects of (R)-ketamine. Eur Arch Psychiatry Clin Neurosci. 2019; 271(3):447-456. PMC: 7981328. DOI: 10.1007/s00406-019-01092-z. View

17.

Lasic E, Lisjak M, Horvat A, Bozic M, Sakanovic A, Anderluh G . Astrocyte Specific Remodeling of Plasmalemmal Cholesterol Composition by Ketamine Indicates a New Mechanism of Antidepressant Action. Sci Rep. 2019; 9(1):10957. PMC: 6662760. DOI: 10.1038/s41598-019-47459-z. View

18.

Zarate Jr C, Singh J, Carlson P, Brutsche N, Ameli R, Luckenbaugh D . A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006; 63(8):856-64. DOI: 10.1001/archpsyc.63.8.856. View

19.

Gittins R, Harrison P . A morphometric study of glia and neurons in the anterior cingulate cortex in mood disorder. J Affect Disord. 2011; 133(1-2):328-32. DOI: 10.1016/j.jad.2011.03.042. View

20.

Beamer L, Carroll S, Eisenberg D . The BPI/LBP family of proteins: a structural analysis of conserved regions. Protein Sci. 1998; 7(4):906-14. PMC: 2143972. DOI: 10.1002/pro.5560070408. View